Skip to main
TVRD

TVRD Stock Forecast & Price Target

TVRD Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 20%
Sell 20%
Strong Sell 0%

Bulls say

Tvardi Therapeutics is well-positioned to capitalize on this unmet need through its innovative approach to targeting STAT3 and potential for successful combination therapies. Their strong pipeline, strategic partnerships, and successful preclinical results bode well for their future success and potential to make a significant impact on improving patients' lives. With a clear focus and promising developments ahead, Tvardi Therapeutics has the potential to see significant growth and success in the biopharmaceutical market.

Bears say

Tvardi Therapeutics is currently facing a number of fundamental challenges that may hinder the success of its pipeline, including regulatory uncertainty, a lack of approved products, and potential challenges in drug delivery for its first-generation direct STAT3 inhibitor, TTI-101. With the recent setback in the REVERT LIVER CANCER trial and the need for additional dosing and clinical data, there is significant risk associated with the company's lead program, TTI-101. Based on current financials and expected developments, we believe that the stock is overvalued and may continue to face significant downward pressure.

TVRD has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cara Therapeutics Inc (TVRD) Forecast

Analysts have given TVRD a Buy based on their latest research and market trends.

According to 5 analysts, TVRD has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cara Therapeutics Inc (TVRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.